Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_058216.3(RAD51C):c.706-13C>G variant causes a splice polypyrimidine tract, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000113 in 1,597,188 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
RAD51C (HGNC:9820): (RAD51 paralog C) This gene is a member of the RAD51 family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51 and are known to be involved in the homologous recombination and repair of DNA. This protein can interact with other RAD51 paralogs and is reported to be important for Holliday junction resolution. Mutations in this gene are associated with Fanconi anemia-like syndrome. This gene is one of four localized to a region of chromosome 17q23 where amplification occurs frequently in breast tumors. Overexpression of the four genes during amplification has been observed and suggests a possible role in tumor progression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Verdict is Likely_benign. Variant got -5 ACMG points.
BP4
?
BP4 - Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.)
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
?
BP6 - Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation
Variant 17-58709846-C-G is Benign according to our data. Variant chr17-58709846-C-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 379592.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=8, Uncertain_significance=1}.
Likely benign, criteria provided, single submitter
curation
Sema4, Sema4
Jul 21, 2020
- -
Uncertain significance, criteria provided, single submitter
clinical testing
Ambry Genetics
Nov 21, 2016
The c.706-13C>G intronic alteration consists of a C to G substitution 13 nucleotides before coding exon 5 in the RAD51C gene. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Likely benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Jul 20, 2015
- -
not specified Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Aug 15, 2023
- -
Breast and/or ovarian cancer Benign:1
Likely benign, criteria provided, single submitter
clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Mar 17, 2022
- -
Fanconi anemia complementation group O;C3150659:Breast-ovarian cancer, familial, susceptibility to, 3 Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Counsyl
Jun 01, 2017
- -
not provided Benign:1
Likely benign, criteria provided, single submitter
clinical testing
GeneDx
Jul 03, 2019
This variant is associated with the following publications: (PMID: 25980754) -
Fanconi anemia complementation group O Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Invitae
Jan 25, 2024
- -
Breast-ovarian cancer, familial, susceptibility to, 3 Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Myriad Genetics, Inc.
Apr 05, 2023
This variant is considered likely benign. This variant is intronic and is not expected to impact mRNA splicing. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -